Breathe Well Live Well
|
AstraZeneca Symbicort shows similar safety profile as Budesonide for asthma
Pharmaceutical Business Review AstraZeneca has published a new study that demonstrates that Symbicort Inhalation Aerosol 320/9 µg twice daily has a safety profile similar to Budesonide pressurized metered-dose inhaler (pMDI) 320 µg twice daily for asthma. SYMBICORT® (budesonide/formoterol fumarate dihydrate) Long-Term Study Shows … |
View full post on asthma – Google News
|
NIH statement on World Asthma Day 2012 – May 1, 2012
Pharmaceutical Processing By National Institutes of Health On World Asthma Day 2012, we at the National Institutes of Health stand with the Global Initiative for Asthma to renew our dedication to improving the quality of life for the millions of people living with asthma. |
View full post on asthma – Google News
|
MediciNova completes enrollment in Phase II asthma trial
Pharmaceutical Business Review MediciNova has completed enrollment in its Phase II trial (MN-221-CL-007) evaluating the safety and efficacy of MN-221 for treatment of acute exacerbations of asthma. The randomized, double-blind trial enrolled a total of 176 asthma patients in the … MediciNova Completes Enrollment in Phase 2 MN-221 Trial Treating Patients … |
View full post on asthma – Google News
 Visit Bulgaria |
GSK, Theravance report completion of Relovair studies in COPD and asthma
Pharmaceutical Business Review GlaxoSmithKline (GSK) and Theravance have announced the completion of the phase III registration programme for the once-daily investigational medicine Relovair used to treat chronic obstructive pulmonary disease (COPD) and asthma. … GSK and Theravance Announce Initial Outcomes From Pivotal Phase III Studies … Theravance Falls Most in 3 Years After Glaxo Drug Fails Glaxo on the slide after trials setback for asthma drug |
View full post on asthma – Google News
|
Merck Dulera shows efficacy in COPD treatment
Pharmaceutical Business Review Dulera Inhalation Aerosol, which is used to treat asthma combines mometasone furoate, an inhaled corticosteroid, and formoterol fumarate, a long-acting beta2-agonist. The two 26-week, multicenter, double-blind, placebo controlled trials comprising 2251 … Merck Announces Presentation of Phase III Investigational Studies Evaluating … |
View full post on asthma – Google News
 MD News (press release) |
Use of Asthma Controller Meds on the Rise Among US Kids
Pharmaceutical Processing According to a report from the US Agency for Healthcare Research and Quality, the percentage of children with asthma in the United States who use a prescription "controller" medicine has nearly doubled since the late 1990s, as reported Thursday in … Pediatric Asthma Drug Prescriptions on the Upswing |
View full post on asthma – Google News
|
Kissei funds for MediciNova asthma drug development
Pharmaceutical Business Review Kissei Pharmaceutical is funding $2.5m to support further clinical development of MediciNova's MN-221 to treat acute exacerbations of asthma or chronic obstructive pulmonary disease (COPD). As per the license agreenent signed between the two companies … MediciNova to Receive $2.5 Million Payment From Kissei Pharmaceutical Co. Ltd … Kissei To Pay MediciNova $2.5 Mln To Support Clinical Development Of MN-221 MediciNova Inc expects USD2.5m from Kissei Pharmaceutical Co Ltd for MN-221 … |
View full post on asthma – Google News
|
MediciNova to Receive $2.5 Million Payment From Kissei Pharmaceutical Co. Ltd …
MarketWatch (press release) Ltd., a pharmaceutical company traded on the Tokyo Stock Exchange (4547), will pay MediciNova $2.5 million, within 30 days, to support further clinical development of MN-221 for the treatment of acute exacerbations of asthma or chronic obstructive … |
View full post on asthma – Google News
|
MediciNova Closes $7.5 Million Private Stock Sale to Kissei Pharmaceutical Co …
MarketWatch (press release) MediciNova's pipeline includes six clinical-stage compounds for the treatment of acute exacerbations of asthma, chronic obstructive pulmonary disease exacerbations, multiple sclerosis and other neurologic conditions, asthma, interstitial cystitis, … |
View full post on asthma – Google News
|
US to phase out OTC asthma inhalers citing environmental concerns
Pharmaceutical Business Review The United States Food and Drug Administration (FDA) announced that over-the-counter (OTC) asthma inhaler, Primatene Mist, containing chlorofluorocarbons (CFCs) will be taken off the US market from 31 December. The CFCs present in the product deplete … Teva Respiratory Provides Resources for Patients Impacted by PRIMATENE(R) MIST … |
View full post on asthma – Google News